INBS

Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.

Wall Street analysts forecast INBS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INBS is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Intelligent Bio Solutions Inc revenue for the last quarter amounts to 1.11M USD, increased 27.46 % YoY.

Intelligent Bio Solutions Inc. EPS for the last quarter amounts to -3.49 USD, decreased -50.50 % YoY.

Intelligent Bio Solutions Inc (INBS) has 16 emplpoyees as of January 07 2026.

Today INBS has the market capitalization of 10.27M USD.